NCI: Breast Cancer Cases Could Rise by 50 Percent

A National Cancer Institute model forecasts a marked increase in estrogen receptor-positive tumors among older women by 2030.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, NCIAs the population of the U.S. grows and the average citizen lives longer, the total number of breast cancer cases among American women could be as much as 50 percent greater in 2030 than it was in 2011, according to a new forecast by the National Cancer Institute (NCI). NCI biostatistician Philip Rosenberg presented the findings yesterday (April 20) at the annual meeting of the American Association for Cancer Research (AACR) being held in Philadelphia.

Rosenberg explained that he NCI model predicts that the proportion of estrogen receptor (ER)-positive, in-situ breast cancer may rise from 19 percent to 29 percent, while rates of ER-negative breast cancer diagnoses will plateau or decrease. “Our estimate is that the total number of diagnoses of breast cancer in the U.S. will increase by about 50 percent by 2030,” he said during a press conference announcing the results. “The one silver lining is that we expect fewer ER-negative tumors, which include the most difficult-to-treat HER2-positive and triple-negative subtypes,” Rosenberg added in a statement.

The total number of new breast cancer cases in the U.S. will likely increase from 283,000 in 2011 to 441,000 in 2030, according to the NCI model, which incorporated data from the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies